Netherlands
# |
Name |
Receivables |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 4.70 B
|
Dec. 31, 2023 | USD 27.32 | 1.49% |
|
Netherlands |
|
2 |
USD 515.64 M
|
Dec. 31, 2023 | USD 44.64 | 0.29% |
|
Netherlands |
|
3 |
USD 499.27 M
|
Dec. 31, 2023 | USD 667.09 | 1.81% |
|
Netherlands |
|
4 |
USD 42.62 M
|
Dec. 31, 2023 | USD 8.76 | -0.46% |
|
Netherlands |
|
5 |
USD 4.19 M
|
Dec. 31, 2023 | USD 15.74 | -0.32% |
|
Netherlands |
|
6 |
USD 3.98 M
|
Dec. 31, 2023 | USD 40.94 | -1.52% |
|
Netherlands |
|
7 |
USD 1.88 M
|
Dec. 31, 2023 | USD 22.29 | 2.39% |
|
Netherlands |
|
8 |
USD 1.70 M
|
Dec. 31, 2023 | USD 0.98 | -1.01% |
|
Netherlands |
|
9 |
USD 1.40 M
|
Dec. 31, 2023 | USD 2.12 | -1.40% |
|
Netherlands |
|
10 |
USD 1.15 M
|
Dec. 31, 2023 | USD 17.60 | -0.73% |
|
Netherlands |
The Biotechnology company in Netherlands with the highest Receivables is Koninklijke Philips N.V. (Amsterdam Stock Exchange: PHIA.AS) at USD 4.70 B.
The Biotechnology company in Netherlands with the lowest Receivables is Pharvaris N.V. (NasdaqGS: PHVS) at USD 1.15 M.
The top 10 Biotechnology companies in Netherlands by Receivables are Koninklijke Philips N.V., Qiagen N.V., argenx SE, Pharming Group N.V., uniQure N.V., Merus N.V., NewAmsterdam Pharma Company N.V., LAVA Therapeutics N.V., ProQR Therapeutics N.V. and Pharvaris N.V..
The bottom 10 Biotechnology companies in Netherlands by Receivables are Pharvaris N.V., ProQR Therapeutics N.V., LAVA Therapeutics N.V., NewAmsterdam Pharma Company N.V., Merus N.V., uniQure N.V., Pharming Group N.V., argenx SE, Qiagen N.V. and Koninklijke Philips N.V..